Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) have received a consensus rating of “Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $49.88.

Several brokerages have recently commented on SUPN. BidaskClub lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC restated a “buy” rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. SunTrust Banks, Inc. restated a “buy” rating and set a $61.00 price target on shares of Supernus Pharmaceuticals in a research note on Friday. Cowen and Company set a $50.00 price target on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 23rd. Finally, Janney Montgomery Scott began coverage on shares of Supernus Pharmaceuticals in a research note on Friday, July 14th. They set a “neutral” rating and a $47.00 price target on the stock.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction on Friday, September 8th. The shares were sold at an average price of $47.60, for a total transaction of $2,380,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Stefan K.F. Schwabe sold 95,000 shares of the company’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $46.59, for a total transaction of $4,426,050.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 153,709 shares of company stock valued at $7,223,108. 6.70% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA boosted its holdings in shares of Supernus Pharmaceuticals by 73.4% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 26,072 shares of the specialty pharmaceutical company’s stock worth $1,043,000 after buying an additional 11,038 shares during the period. Candriam Luxembourg S.C.A. boosted its holdings in shares of Supernus Pharmaceuticals by 25.4% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 89,000 shares of the specialty pharmaceutical company’s stock worth $3,560,000 after buying an additional 18,000 shares during the period. Cim LLC bought a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at $488,000. Scout Investments Inc. boosted its holdings in Supernus Pharmaceuticals by 239.5% in the 3rd quarter. Scout Investments Inc. now owns 565,900 shares of the specialty pharmaceutical company’s stock valued at $22,636,000 after purchasing an additional 399,225 shares during the period. Finally, Keybank National Association OH bought a new stake in Supernus Pharmaceuticals in the 3rd quarter valued at $915,000. 95.06% of the stock is owned by institutional investors and hedge funds.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded up $0.55 on Friday, hitting $42.05. 319,070 shares of the stock traded hands, compared to its average volume of 361,063. Supernus Pharmaceuticals has a 52 week low of $17.25 and a 52 week high of $50.04. The firm has a market cap of $2,131.89, a price-to-earnings ratio of 36.89, a price-to-earnings-growth ratio of 1.84 and a beta of 1.30. The company has a current ratio of 1.94, a quick ratio of 1.74 and a debt-to-equity ratio of 0.01.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. research analysts anticipate that Supernus Pharmaceuticals will post 1.04 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals, Inc. (SUPN) Receives Consensus Rating of “Buy” from Analysts” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/05/supernus-pharmaceuticals-inc-supn-receives-consensus-rating-of-buy-from-analysts-2.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.